Autopsy report · NCT00644306

Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“survival advantage demonstrated”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 years 11 months after it had already started.
Ran for about 5 years 1 month before it stopped.
232 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Central Hospital, Nancy, France
Sponsor type: University, hospital or other
Conditions: Newly Diagnosed, Multiple Myeloma
Interventions: Thalidomide; melphalan, prednisone; melphalan, prednisone, thalidomide
Participants: 232
Sites: 1
Countries: France

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.